Neuphoria Therapeutics secures milestone payment from Merck as Alzheimer’s clinical trial advances
Neuphoria Therapeutics Inc. (Nasdaq: NEUP), a late-stage biotechnology company focused on developing treatments for neuropsychiatric disorders, has announced that it will receive a $15 million ... Read More
Merck initiates Phase 3 waveLINE-010 trial for zilovertamab vedotin in diffuse large B-cell lymphoma
Merck, known as MSD outside the United States and Canada, has launched its pivotal Phase 3 waveLINE-010 clinical trial, evaluating the investigational antibody-drug conjugate (ADC) ... Read More
Merck invests $50m in Personalis to bolster Moderna collaboration on individualized cancer therapies
Personalis, Inc., a leader in precision oncology solutions, has secured a significant investment from Merck and extended its partnership with Moderna. These strategic agreements aim ... Read More
Merck’s WELIREG receives positive CHMP opinion for VHL tumours and advanced RCC
Merck, known as MSD outside the U.S. and Canada, has moved a step closer to offering innovative treatment options in Europe. The European Medicines Agency’s ... Read More
Merck licenses innovative anti-cancer therapy LM-299 from LaNova Medicines
In a strategic move to broaden its oncology portfolio, Merck & Co., Inc. (NYSE: MRK), recognized globally as MSD outside the U.S. and Canada, has ... Read More
Merck’s $1.3bn bet on cancer therapy: Inside the Modifi Biosciences acquisition
Merck & Co., a global leader in pharmaceuticals, has acquired Modifi Biosciences, a cutting-edge biotech startup based in New Haven, Connecticut, for up to $1.3 ... Read More
Breakthrough liver cancer treatment: Merck’s new drug combo slashes disease progression risk by 34%
Merck & Co., Inc. (known as MSD outside the United States and Canada) and Eisai Co., Ltd. have announced encouraging results from the first interim ... Read More
Health Canada approves KEYTRUDA and Enfortumab Vedotin for advanced urothelial cancer
Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced that Health Canada has granted approval for KEYTRUDA (pembrolizumab) in combination ... Read More
Merck secures exclusive global license for opevesostat from Orion Corporation
Merck (NYSE: MRK), also known as MSD outside the United States and Canada, has enhanced its strategic position in the oncology market by securing an ... Read More
Merck to acquire EyeBio in $3bn deal to expand ophthalmology pipeline
Merck (NYSE: MRK), also known as MSD outside of the United States and Canada, has announced a definitive agreement to acquire EyeBio Limited, a prominent ... Read More